A citation-based method for searching scientific literature

Masashi Tanaka, Hajime Yamakage, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Akira Shimatsu, Noriko Satoh-Asahara. Intern Med 2020
Times Cited: 4







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
75

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
353
50

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.
Kazuomi Kario, Kenta Okada, Mitsunobu Murata, Daisuke Suzuki, Kayo Yamagiwa, Yasuhisa Abe, Isao Usui, Norihiro Tsuchiya, Chie Iwashita, Noriko Harada,[...]. J Clin Hypertens (Greenwich) 2020
14
50

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen. Diabetes Obes Metab 2018
115
50

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
217
50

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
150
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
25


Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease.
Colin Cunnington, Tim Van Assche, Cheerag Shirodaria, Ilias Kylintireas, Alistair C Lindsay, Justin M Lee, Charalambos Antoniades, Marios Margaritis, Regent Lee, Ruha Cerrato,[...]. Circulation 2012
108
25

AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice.
Xue Gao, Hanrui Zhang, Ann Marie Schmidt, Cuihua Zhang. Am J Physiol Heart Circ Physiol 2008
118
25

The roles of epicardial adipose tissue in heart failure.
Ying Song, Fei Song, Chan Wu, Yi-Xiang Hong, Gang Li. Heart Fail Rev 2022
7
25

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
732
25

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A DeFronzo. Curr Diab Rep 2012
73
25


Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.
Kerstin Nowotny, Tobias Jung, Annika Höhn, Daniela Weber, Tilman Grune. Biomolecules 2015
407
25

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
254
25

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Rev Esp Cardiol (Engl Ed) 2016
235
25

Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
Tomonari Kimura, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Kaoru Akazawa, Yukihiro Saito, Satoshi Akagi, Yuko Ohno, Megumi Kondo, Daiji Miura,[...]. Int Heart J 2019
8
25

Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Tomoe Y Nakamura, Yuko Iwata, Yuji Arai, Kazuo Komamura, Shigeo Wakabayashi. Circ Res 2008
129
25

The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA).
Evrim B Turkbey, Robyn L McClelland, Richard A Kronmal, Gregory L Burke, Diane E Bild, Russell P Tracy, Andrew E Arai, João A C Lima, David A Bluemke. JACC Cardiovasc Imaging 2010
206
25

Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis.
Xiaoyan Cai, Yunlong Zhang, Meijun Li, Jason Hy Wu, Linlin Mai, Jun Li, Yu Yang, Yunzhao Hu, Yuli Huang. BMJ 2020
76
25

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Naveed Sattar, Björn Eliasson, Ann-Marie Svensson, Björn Zethelius, Mervete Miftaraj, Darren K McGuire, Annika Rosengren,[...]. N Engl J Med 2018
437
25

Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states.
David Furman, Junlei Chang, Lydia Lartigue, Christopher R Bolen, François Haddad, Brice Gaudilliere, Edward A Ganio, Gabriela K Fragiadakis, Matthew H Spitzer, Isabelle Douchet,[...]. Nat Med 2017
170
25

Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
Joshua M Hare, Brian Mangal, Joanne Brown, Charles Fisher, Ronald Freudenberger, Wilson S Colucci, Douglas L Mann, Peter Liu, Michael M Givertz, Richard P Schwarz. J Am Coll Cardiol 2008
260
25

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Seok Joon Shin, Sungjin Chung, Soo Jung Kim, Eun-Mi Lee, Young-Hye Yoo, Ji-Won Kim, Yu-Bae Ahn, Eun-Sook Kim, Sung-Dae Moon, Myung-Jun Kim,[...]. PLoS One 2016
82
25

Insulin signalling in the heart.
Luc Bertrand, Sandrine Horman, Christophe Beauloye, Jean-Louis Vanoverschelde. Cardiovasc Res 2008
173
25

Metabolic inflammation in heart failure with preserved ejection fraction.
Gabriele G Schiattarella, Daniele Rodolico, Joseph A Hill. Cardiovasc Res 2021
17
25


Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Seizo Okauchi, Masashi Shimoda, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Kenji Kohara, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto. Biochem Biophys Res Commun 2016
34
25

The pathophysiological role of interstitial sodium in heart failure.
Petra Nijst, Frederik H Verbrugge, Lars Grieten, Matthias Dupont, Paul Steels, W H Wilson Tang, Wilfried Mullens. J Am Coll Cardiol 2015
73
25

Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
Amy Groenewegen, Frans H Rutten. Eur J Heart Fail 2020
2
50

Insulin resistance and heart failure: molecular mechanisms.
Annayya R Aroor, Chirag H Mandavia, James R Sowers. Heart Fail Clin 2012
106
25

Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.
Tatsuya Fukuda, Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama,[...]. Diabetes Ther 2017
47
25

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
582
25

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama,[...]. Cardiovasc Diabetol 2017
69
25

Prognosis of patients eligible for dapagliflozin in acute heart failure.
Sebastian Carballo, Jérôme Stirnemann, Nicolas Garin, Pauline Darbellay Farhoumand, Jacques Serratrice, David Carballo. Eur J Clin Invest 2020
1
100




Hyperuricemia as a risk factor for cardiovascular disease.
Niki Katsiki, Michael Doumas, Vasilios G Athyros, Asterios Karagiannis. Expert Rev Cardiovasc Ther 2015
17
25

Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance.
Hideaki Kaneto, Atsushi Obata, Tomohiko Kimura, Masashi Shimoda, Seizo Okauchi, Naoki Shimo, Taka-Aki Matsuoka, Kohei Kaku. J Diabetes 2017
32
25

Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction--a meta analysis of 7 prospective clinical studies.
Mingqiang Fu, Jingmin Zhou, Aijun Sun, Shuning Zhang, Chunyu Zhang, Yunzeng Zou, Michael Fu, Junbo Ge. Int J Cardiol 2012
38
25

Treating oxidative stress in heart failure: past, present and future.
Atze van der Pol, Wiek H van Gilst, Adriaan A Voors, Peter van der Meer. Eur J Heart Fail 2019
112
25

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Gianluigi Savarese, Naveed Sattar, James Januzzi, Subodh Verma, Lars H Lund, David Fitchett, Cordula Zeller, Jyothis T George, Martina Brueckmann, Anne Pernille Ofstad,[...]. Circulation 2019
25
25

Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.
Shi Fang Yan, Ravichandran Ramasamy, Yoshifumi Naka, Ann Marie Schmidt. Circ Res 2003
368
25

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
160
25

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Scott D Solomon, John J V McMurray, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske,[...]. N Engl J Med 2019
578
25

The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings.
Beatriz Paradela-Dobarro, Rosa M Agra, Leyre Álvarez, Alfonso Varela-Román, José M García-Acuña, José R González-Juanatey, Ezequiel Álvarez, Francisco J García-Seara. Nutr Metab Cardiovasc Dis 2019
7
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.